drugset / Trial / NCT05458479

Fluoxetine Treatment of Depression in Down Syndrome

NCT05458479

Phase 4 Completed 4 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to do a preliminary assessment of whether fluoxetine is effective, safe, and tolerable for the treatment of depression in adults with Down syndrome.

Timeline

Start
2022-12-05
Primary completion
2024-02-26
Completion
2024-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 30 mg Oral